Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wen-Juei Jeng

Showing results (1-10 of 172) with videos related to

Pageof 18
Sort By:
Hepatology (Baltimore, Md.)|May 15, 2014
Finite entecavir therapy is a feasible alternative to indefinite therapyWen-Juei Jeng
Clinical Liver Disease|April 29, 2024
How to achieve a functional cure for chronic hepatitis B infectionWen-Juei Jeng, Anna S Lok
Gut|December 1, 2019
Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patientsYun-Fan Liaw, Wen-Juei Jeng
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 21, 2020
Should Treatment Indications for Chronic Hepatitis B Be Expanded?Wen-Juei Jeng, Anna S Lok
Hepatology International|May 17, 2022
Unsolved issues in treatment for grey zone chronic hepatitis B patientsWen-Juei Jeng, Rong-Nan Chien
Journal of Hepatology|September 19, 2024
Prediction of HBsAg loss after cessation of entecavir therapyYun-Fan Liaw, Wen-Juei Jeng
Journal of Viral Hepatitis|May 5, 2019
Discrepant range of sPD-1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis BWen-Juei Jeng, Hwai-I Yang
Journal of Hepatology|March 20, 2017
Serum HBsAg kinetics in clinical predictionWen-Juei Jeng, Yun-Fan Liaw
Alimentary Pharmacology & Therapeutics|February 14, 2023
Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patientsYen-Chun Liu, Wen-Juei Jeng
Seminars in Liver Disease|October 1, 2021
Erratum to: Finite Antiviral Therapy in Chronic Hepatitis B Patients with CirrhosisWen-Juei Jeng, Yun-Fan Liaw
Pageof 18

Showing results (1-10 of 172) with videos related to

Sort By:
Pageof 18
Hepatology (Baltimore, Md.)|May 15, 2014
Finite entecavir therapy is a feasible alternative to indefinite therapyWen-Juei Jeng
Clinical Liver Disease|April 29, 2024
How to achieve a functional cure for chronic hepatitis B infectionWen-Juei Jeng, Anna S Lok
Gut|December 1, 2019
Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patientsYun-Fan Liaw, Wen-Juei Jeng
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 21, 2020
Should Treatment Indications for Chronic Hepatitis B Be Expanded?Wen-Juei Jeng, Anna S Lok
Hepatology International|May 17, 2022
Unsolved issues in treatment for grey zone chronic hepatitis B patientsWen-Juei Jeng, Rong-Nan Chien
Journal of Hepatology|September 19, 2024
Prediction of HBsAg loss after cessation of entecavir therapyYun-Fan Liaw, Wen-Juei Jeng
Journal of Viral Hepatitis|May 5, 2019
Discrepant range of sPD-1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis BWen-Juei Jeng, Hwai-I Yang
Journal of Hepatology|March 20, 2017
Serum HBsAg kinetics in clinical predictionWen-Juei Jeng, Yun-Fan Liaw
Alimentary Pharmacology & Therapeutics|February 14, 2023
Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patientsYen-Chun Liu, Wen-Juei Jeng
Seminars in Liver Disease|October 1, 2021
Erratum to: Finite Antiviral Therapy in Chronic Hepatitis B Patients with CirrhosisWen-Juei Jeng, Yun-Fan Liaw
Pageof 18